Healthineers first-quarter earnings lower on ramp-up costs

FRANKFURT (Reuters) – Siemens Healthineers’ (DE:) operating income slipped 11% in the first quarter of its fiscal year, despite higher revenues, as it sold less profitable imaging machines and incurred ramp-up costs for its new Atellica blood-testing machines.

The German maker of diagnostic equipment said adjusted earnings before interest and tax declined to 484 million euros ($536 million) during the October-December period.

That was below an average analyst estimate of 568 million euros, according to a consensus posted on the company’s website.

“Profitability was negatively impacted by a temporary dip in Imaging and the guided weak margin performance in Diagnostics,” the group said in a statement on Monday.

Atellica ramp-up costs were inflated by the shipment of more than 600 analyzers from July to September last year, it added.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.